Brivaracetam as adjunctive therapy for the treatment of partial-onset seizures in patients with epilepsy: the current evidence base

被引：18

作者：

Brandt, Christian ^{[1
]}

May, Theodor W. ^{[2
]}

Bien, Christian G. ^{[1
]}

机构：

[1] Bethel Epilepsy Ctr, Maraweg 21, D-33617 Bielefeld, Germany

[2] Epilepsy Res Soc, Bielefeld, Germany

来源：

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS | 2016年 / 9卷 / 06期

关键词：

efficacy; interactions; levetiracetam; pharmacogenetics; pharmacokinetics; safety; SV2A; therapeutic drug monitoring; SYNAPTIC VESICLE PROTEIN; PLACEBO-CONTROLLED TRIAL; ADVERSE EVENT PROFILE; DOUBLE-BLIND; SV2A LIGAND; IN-VITRO; CNS PHARMACODYNAMICS; HEALTHY-SUBJECTS; FOCAL EPILEPSY; PHASE-III;

D O I：

10.1177/1756285616665564

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

100204 [神经病学];

摘要：

Brivaracetam (BRV) is a novel antiepileptic drug recently licensed for the treatment of partial epilepsy in adults and adolescents over 16 years old. Like levetiracetam (LEV), it is a ligand of the synaptic vesicle protein SV2A. BRV has been shown in animal models and in studies using human brain slices to have a higher SV2A affinity and faster penetration into the brain. Its efficacy and safety have been shown in several randomized, controlled studies. The recommended initial dose is 50-100 mg, divided into two daily doses. Up-titration to a 200 mg daily dose is possible. Dizziness and somnolence are frequent side effects. There are some hints that BRV may be less frequently associated with behavioural adverse events than LEV. Long-term efficacy and safety and BRV use in special patient groups have to be assessed in the future.

引用

页码：474 / 482

页数：9

共 49 条

[1]

Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: A phase III randomized, double-blind, placebo-controlled trial [J].

Biton, Victor ;

Berkovic, Samuel F. ;

Abou-Khalil, Bassel ;

Sperling, Michael R. ;

Johnson, Martin E. ;

Lu, Sarah .

EPILEPSIA, 2014, 55 (01) :57-66

[2]

Therapeutic drug monitoring in epileptology and psychiatry [J].

Brandt, C. ;

Baumann, P. ;

Eckermann, G. ;

Hiemke, C. ;

May, T. W. ;

Rambeck, B. ;

Pohlmann-Eden, B. .

NERVENARZT, 2008, 79 (02) :167-174

[3]

Cognitive adverse events of topiramate in patients with epilepsy and intellectual disability [J].

Brandt, Christian ;

Lahr, Denise ;

May, Theodor W. .

EPILEPSY & BEHAVIOR, 2015, 45 :261-264

[4]

Therapeutic drug monitoring of newer antiepileptic drugs [J].

Brandt, Christian ;

May, Theodor W. .

LABORATORIUMSMEDIZIN-JOURNAL OF LABORATORY MEDICINE, 2011, 35 (03) :161-169

[5]

Brivaracetam does not alter spatial learning and memory in both normal and amygdala-kindled rats [J].

Detrait, E. R. ;

Leclercq, K. ;

Loescher, W. ;

Potschka, H. ;

Niespodziany, I. ;

Hanon, E. ;

Kaminski, R. M. ;

Matagne, A. ;

Lamberty, Y. .

EPILEPSY RESEARCH, 2010, 91 (01) :74-83

[6]

Anti-ictogenic and antiepileptogenic properties of brivaracetam in mature and immature rats [J].

Dupuis, Nina ;

Matagne, Alain ;

Staelens, Ludovicus ;

Dournaud, Pascal ;

Desnous, Beatrice ;

Gressens, Pierre ;

Auvin, Stephane .

EPILEPSIA, 2015, 56 (05) :800-805

[7]

*FOOD DRUG ADM, 1997, COD SYMB THES ADV RE

[8]

A systematic review of the safety profile of levetiracetam: a new antiepileptic drug [J].

French, J ;

Edrich, P ;

Cramer, JA .

EPILEPSY RESEARCH, 2001, 47 (1-2) :77-90

[9]

Adjunctive brivaracetam for refractory partial-onset seizures A randomized, controlled trial [J].

French, J. A. ;

Costantini, C. ;

Brodsky, A. ;

von Rosenstiel, P. .

NEUROLOGY, 2010, 75 (06) :519-525

[10]

In vitro models for the blood-brain barrier [J].

Garberg, P ;

Ball, M ;

Borg, N ;

Cecchelli, R ;

Fenart, L ;

Hurst, RD ;

Lindmark, T ;

Mabondzo, A ;

Nilsson, JE ;

Raub, TJ ;

Stanimirovic, D ;

Terasaki, T ;

Öberg, JO ;

Österberg, T .

TOXICOLOGY IN VITRO, 2005, 19 (03) :299-334

← 1 2 3 4 5 →